Because IBD patient-derived endogenous IgA has an aberrant binding ability to gut bacteria, we hypothesized that oral treatment of mouse IgA, which binds selectively to colitogenic bacteria, may ameliorate dysbiosis in IBD patients. The gene discussed is CD79A; the disease is inflammatory bowel disease.